QSAM Biosciences, Inc. develops nuclear medicines for cancer treatment and related illnesses. Their flagship project is CycloSam, a radiopharmaceutical that targets bone tissue in late-stage clinical testing. Headquartered in Austin, Texas, the company originated as Q2Earth and changed its name in September 2020.